Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octanorm (Cutaquig) in Dermatomyositis
NCT03686969Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in dermatomyositis (DM), sponsored by Octapharma. Started Aug 2018; status: terminated.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT03686969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686969.